← All trials
NCT06253988
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- Feb 1, 2023
- Completion date
- Sep 30, 2023
- First posted
- Feb 12, 2024
- Last posted
- Feb 12, 2024
- Enrollment
- 65
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Al Azhar UniversityLead sponsor
- Al Azhar UniversityOfficial
- Assiut UniversityOfficial
- Sphinx universitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.